Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Med Trop Sante Int ; 3(1)2023 03 31.
Article in French | MEDLINE | ID: mdl-37389381

ABSTRACT

Source of many myths, French Guiana represents an exceptional territory due to the richness of its biodiversity and the variety of its communities. The only European territory in Amazonia, surrounded by the Brazilian giant and the little-known Suriname, Ariane 6 rockets are launched from Kourou while 50% of the population lives below the poverty line. This paradoxical situation is a source of health problems specific to this territory, whether they be infectious diseases with unknown germs, intoxications or chronic pathologies.Some infectious diseases such as Q fever, toxoplasmosis, cryptococcosis or HIV infection are in common with temperate countries, but present specificities leading to sometimes different management and medical reasoning. In addition to these pathologies, many tropical diseases are present in an endemic and / or epidemic mode such as malaria, leishmaniasis, Chagas disease, histoplasmosis or dengue. Besides, Amazonian dermatology is extremely varied, ranging from rare but serious pathologies (Buruli ulcer, leprosy) to others which are frequent and benign such as agouti lice (mites of the family Trombiculidae) or papillonitis. Envenomations by wild fauna are not rare, and deserve an appropriate management of the incriminated taxon. Obstetrical, cardiovascular and metabolic cosmopolitan pathologies sometimes take on a particular dimension in French Guiana that must be taken into account in the management of patients. Finally, different types of intoxication are to be known by practitioners, especially due to heavy metals.European-level resources offer diagnostic and therapeutic possibilities that do not exist in the surrounding countries and regions, thus allowing the management of diseases that are not well known elsewhere.Thanks to these same European-level resources, research in Guyana occupies a key place within the Amazon region, despite a smaller population than in the surrounding countries. Thus, certain pathologies such as histoplasmosis of the immunocompromised patient, Amazonian toxoplasmosis or Q fever are hardly described in neighboring countries, probably due to under-diagnosis linked to more limited resources. French Guiana plays a leading role in the study of these diseases.The objective of this overview is to guide health care providers coming to or practicing in French Guiana in their daily practice, but also practitioners taking care of people returning from French Guiana.


Subject(s)
Communicable Diseases , Cuniculidae , HIV Infections , Histoplasmosis , Noncommunicable Diseases , Q Fever , Toxoplasmosis , Animals , Humans , French Guiana/epidemiology , Toxoplasmosis/diagnosis
2.
Infect Dis Poverty ; 9(1): 19, 2020 Feb 13.
Article in English | MEDLINE | ID: mdl-32051036

ABSTRACT

BACKGROUND: Mycobacterium leprae and Toxoplasma gondii infections are both neglected tropical diseases highly prevalent in Brazil. Infection with certain parasite species can significantly alter susceptibility to other important pathogens, and/or influence the development of pathology. Here we investigated the possible influence of M. leprae/T. gondii co-parasitism on the manifestation of leprosy and its clinical forms. METHODS: Participants (n = 291) were recruited in Campos dos Goytacazes city, Rio de Janeiro state, southeast Brazil, from August 2015 to December 2019 and clinically diagnosed for leprosy. Participants were selected based on the presence (patients) or absence (healthy controls) of the leprosy disease. Contacts of patients were also recruited for this study. Serum samples from patients (n = 199) with leprosy, contacts (n = 40) and healthy controls (n = 52) were investigated for levels of IgM and IgG anti-phenolic glycolipid-1 (PGL-1) by ELISA. Additionally, IgG antibody against soluble Toxoplasma antigen (STAg) was measured in sera samples from leprosy patients, contacts and healthy controls for Toxoplasma gondii serology by ELISA. Anti-PGL-1 IgG and IgM levels were compared using one-way ANOVA Kruskal-Wallis or Mann-Whitney, while Spearman test was used to correlate levels of IgG anti-STAg and IgM/IgG anti-PGL-1 from seropositive and seronegative individuals for T. gondii infection. The risk of T. gondii infection for leprosy disease was assessed using Fisher's test. RESULTS: Levels of IgM anti-PGL-1 antibodies were significantly higher in multibacillary (MB) patients compared to paucibacillary (PB) patients (P = 0.0068). Higher IgM and IgG levels anti-PGL-1 were detected in patients with the lepromatous forms. The serologic prevalence for T. gondii infection was 74.9%. We detected increased anti-STAg antibody levels in leprosy patients (79.4%), reaching 88.8% within those with lepromatous form of this disease. The leprosy risk increase in T. gondii seropositive individuals was two-fold (odds ratio [OR] = 2.055; 95% confidence intervals [95% CI]: 1.18-3.51) higher than those seronegative, and considering the lepromatous leprosy risk this increase was even dramatic (OR = 4.33; 95% CI: 1.76-9.69) in T. gondii seropositive individuals. Moreover the leprosy risk in T. gondii seropositive individuals was weakly correlated to the levels of IgG anti-STAg and IgM/IgG anti-PGL-1. CONCLUSIONS: Altogether, our results suggest that T. gondii infection may exert immunomodulatory properties that influence to the susceptibility of leprosy, mainly on its more severe clinical form. A better understanding of parasite immunomodulation can ultimately contribute to the development of medical applications.


Subject(s)
Antibodies, Bacterial/blood , Leprosy, Lepromatous/epidemiology , Mycobacterium leprae/immunology , Toxoplasma/immunology , Toxoplasmosis/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Brazil/epidemiology , Case-Control Studies , Child , Comorbidity , Enzyme-Linked Immunosorbent Assay , Female , Glycolipids/immunology , Humans , Immunoglobulin G/immunology , Immunoglobulin M/immunology , Male , Middle Aged , Seroepidemiologic Studies , Young Adult
3.
Palmas; [S.n]; 2020. 15 p.
Non-conventional in Portuguese | LILACS, CONASS, Coleciona SUS, SES-TO | ID: biblio-1140431

ABSTRACT

Apresenta o informe epidemiológico do Tocantins dando alusão aos Número de Casos de Beribéri, Doenças Crônicas, Taxa de óbitos por acidente de transporte terrestre, Acidentes de Trânsito, Coberturas das Vacinas, casos confirmados de meningites por etiologia, Hanseníase, tuberculose, doenças diarreica aguda, Toxoplasmose Gestacional e Congênita, HIV/AIDS, hepatites virais no ano de 2020.


It presents the epidemiological report of Tocantins alluding to the Number of Beriberi Cases, Chronic Diseases, Death rate due to land transport accidents, Traffic Accidents, Vaccine Coverage, confirmed cases of meningitis by etiology, Hansen's disease, tuberculosis, acute diarrheal diseases, Gestational and Congenital Toxoplasmosis, HIV / AIDS, viral hepatitis in 2020.


Presenta el informe epidemiológico de Tocantins referido al Número de Casos de Beriberi, Enfermedades Crónicas, Tasa de mortalidad por accidentes de transporte terrestre, Accidentes de tráfico, Cobertura de vacunas, Casos confirmados de meningitis por etiología, Enfermedad de Hansen, Tuberculosis, Enfermedades diarreicas agudas Toxoplasmosis gestacional y congénita, VIH / SIDA, hepatitis viral en 2020.


Il présente le rapport épidémiologique de Tocantins faisant allusion au nombre de cas de béribéri, aux maladies chroniques, au taux de mortalité dû aux accidents de transport terrestre, aux accidents de la circulation, à la couverture vaccinale, aux cas confirmés de méningite par étiologie, à la maladie de Hansen, à la tuberculose, aux maladies diarrhéiques aiguës, Toxoplasmose gestationnelle et congénitale, VIH / SIDA, hépatite virale en 2020.


Subject(s)
Humans , Accidents, Traffic/statistics & numerical data , Annual Report , Tuberculosis , Toxoplasmosis , Chronic Disease/epidemiology , Acquired Immunodeficiency Syndrome , HIV , Dysentery , Vaccine-Preventable Diseases , Leprosy , Meningitis
4.
Dermatol Clin ; 28(3): 599-610, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20510768

ABSTRACT

After synthesis of dapsone (4,4' diaminodiphenylsulfone) in 1908, the compound was known exclusively in chemistry. Following the epoch-making discovery of the antimicrobial potential for sulfonamides emerged, the sulfone class was included in the medical armamentarium. The therapeutic role of sulfones related to both pathogen-caused diseases and chronic inflammatory dermatoses has led to extensive use in dermatology. At present dapsone is the only sulfone congener available for clinical practice. The sulfone is used in rifampin-based multiple-drug regiments to treat multibacillary and paucibacillary leprosy and to treat Pneumocystis jiroveci pneumonia and prevent toxoplasmosis in individuals with AIDS. In dermatology, dapsone is the preferred drug for treating dermatitis herpetiformis (Duhring's disease) and is useful in the management of a broad range of chronic inflammatory entities, especially autoimmune bullous disorders. With proper administration and monitoring, the sulfone should be considered a useful and safe agent.


Subject(s)
Anti-Infective Agents/therapeutic use , Dapsone/therapeutic use , Skin Diseases/drug therapy , Therapies, Investigational , Adult , Anti-Infective Agents/adverse effects , Anti-Infective Agents/chemistry , Anti-Infective Agents/pharmacology , Autoimmune Diseases/drug therapy , Child , Dapsone/adverse effects , Dapsone/chemistry , Dapsone/pharmacology , Humans , Hypersensitivity/etiology , Jaundice/chemically induced , Leprosy/drug therapy , Orphan Drug Production , Peripheral Nervous System Diseases/chemically induced , Pneumocystis carinii/drug effects , Pneumonia, Pneumocystis/drug therapy , Toxoplasmosis/drug therapy
5.
In. Veronesi, Ricardo; Focaccia, Roberto. Tratado de infectologia: v.2. Säo Paulo, Atheneu, 2 ed; 2002. p.1646-1654, ilus, tab. (BR).
Monography in Portuguese | LILACS, Sec. Est. Saúde SP | ID: lil-317793
6.
Bauru; s.n; 1998. 16 p. ilus, tab, 30cm.
Non-conventional in Portuguese | LILACS, HANSEN, Hanseníase Leprosy, SESSP-ILSLPROD, Sec. Est. Saúde SP, SESSP-ILSLACERVO, Sec. Est. Saúde SP, SESSP-PAPSESSP, Sec. Est. Saúde SP | ID: biblio-1084956
10.
J Clin Lab Immunol ; 35(2): 89-93, 1991 Jun.
Article in English | MEDLINE | ID: mdl-1688166

ABSTRACT

A case of chronic mucocutaneous candidiasis in a Malaysian child who subsequently developed disseminated tuberculosis and toxoplasmosis is described. The phenotype of her peripheral blood mononuclear cells showed discordance for her T cell markers. The presence of a subpopulation of CD2-/CD3+ mononuclear cells leading to an immunodeficiency state is consistent with failure of activation of CD2-mediated alternative pathway resulting in immunodeficiency. Such abnormal CD2-/CD3+ subpopulations have been described in lepromatous leprosy and foetal abortuses.


Subject(s)
Antigens, Differentiation, T-Lymphocyte , CD3 Complex/analysis , Candidiasis, Chronic Mucocutaneous/complications , Candidiasis, Oral/complications , Immunologic Deficiency Syndromes/complications , Opportunistic Infections/complications , Receptors, Immunologic , T-Lymphocyte Subsets/immunology , Antigens, Differentiation, T-Lymphocyte/genetics , CD2 Antigens , Candidiasis, Chronic Mucocutaneous/immunology , Candidiasis, Oral/immunology , Disease Susceptibility/immunology , Female , Genetic Predisposition to Disease , Humans , Immunocompromised Host , Immunologic Deficiency Syndromes/genetics , Immunologic Deficiency Syndromes/immunology , Infant , Lymphocyte Activation , Opportunistic Infections/immunology , Receptors, Immunologic/genetics , Toxoplasmosis/complications , Toxoplasmosis/immunology , Tuberculosis/complications , Tuberculosis/immunology
11.
Jpn J Med Sci Biol ; 42(5-6): 163-8, 1989.
Article in English | MEDLINE | ID: mdl-2699622

ABSTRACT

Sera from 140 lepromatous leprosy patients (test group) and 120 normal persons, who showed no clinical signs of acute or chronic toxoplasmosis (control group), were studied for the presence of Toxoplasma gondii antibody by indirect hemagglutination and indirect-immunofluorescent antibody tests. Both tests showed a high incidence of Toxoplasma antibody in the test group in comparison with the control group. IgM and IgG classes of antibody responses were observed in both the groups, which signified recent as well as past infections in them.


Subject(s)
Antibodies, Protozoan/analysis , Leprosy, Lepromatous/immunology , Toxoplasma/immunology , Adult , Aged , Animals , Female , Fluorescent Antibody Technique , Humans , Male , Middle Aged , Rats , Toxoplasmosis/complications
12.
Hybridoma ; 7(2): 167-76, 1988 Apr.
Article in English | MEDLINE | ID: mdl-2897326

ABSTRACT

A mouse monoclonal antibody (HC1/1) specific for a differentiation marker of human monocytes and granulocytes has been generated by using as immunogen the monocytic cell line U937 differentiated with phorbol esters. This differentiation antigen has been characterized as the p150/95 member of the CD11 family of glycoproteins by cellular distribution studies, immunoprecipitation and competition experiments with MAb 3.9 specific for the CD11c antigen. Immuno-alkaline phosphatase staining of normal tissue sections with the HC1/1 MAb demonstrated that the CD11c antigen is a useful macrophage marker. Furthermore, the MAb HC1/1 stains specifically populations of macrophages on skin and lymph node sections from different pathologies such as Sarcoidosis, Granuloma annulare, Lepromatous leprosy and Toxoplasmosis.


Subject(s)
Antibodies, Monoclonal/immunology , Antigens, Differentiation/immunology , CD11 Antigens , Cell Differentiation/drug effects , Cell Line , Humans , Immunization , Leprosy/immunology , Leprosy/pathology , Macrophages/cytology , Macrophages/immunology , Monocytes/cytology , Monocytes/drug effects , Monocytes/immunology , Sarcoidosis/immunology , Sarcoidosis/pathology , Tetradecanoylphorbol Acetate/pharmacology , Toxoplasmosis/immunology , Toxoplasmosis/pathology
13.
Exp Parasitol ; 62(1): 79-84, 1986 Aug.
Article in English | MEDLINE | ID: mdl-3720902

ABSTRACT

A radioimmunoassay for the quantitative determination of antileishmanial antibody in sera from patients suffering from cutaneous leishmaniasis was developed. The assay, using as antigen either the soluble fraction from freeze-thawed sonicated Leishmania major (LRC-L137) promastigotes or a carbohydrate-lipid containing fraction obtained by extraction with hexane-isopropanol, was shown to be sensitive and reproducible. The sera of 95 patients were examined. These were from patients with cutaneous leishmaniasis (26 from the Jordan Valley and 13 from Sinai), kala-azar (9), malaria (24), schistosomiasis (10), toxoplasmosis (5), and leprosy (8); controls were 37 normal human sera. No significant antigen dependent differences were observed using sera from cutaneous leishmaniasis patients, although differences in the immunological response were observed between the two populations of these patients. Antileishmanial activity was not detected in sera from patients with malaria, schistosomiasis, or toxoplasmosis. Although sera from leprosy patients crossreacted with the carbohydrate-lipid containing fraction, it was nevertheless more strain specific than freeze thawed sonicated L. major.


Subject(s)
Antibodies/analysis , Leishmania tropica/immunology , Leishmaniasis/immunology , Antigens, Protozoan/immunology , Humans , Leishmaniasis, Visceral/immunology , Malaria/immunology , Radioimmunoassay , Schistosomiasis/immunology , Toxoplasmosis/immunology
14.
Z Hautkr ; 59(3): 160, 163-4, 171, 1984 Feb 01.
Article in German | MEDLINE | ID: mdl-6719975

ABSTRACT

We report on granulomatous infections of the skin, as well as the current state of therapeutics. Cutaneous tuberculosis and presently desired therapeutic regiments are treated in detail. Diseases regarded as eradicated in Germany, such as brucellosis and listeriosis, do still occur. Their recognition and cure are discussed from a modern point of view.


Subject(s)
Granuloma/drug therapy , Skin Diseases, Infectious/drug therapy , Antitubercular Agents/therapeutic use , Dermatomycoses/drug therapy , Drug Therapy, Combination , Humans , Leishmaniasis/drug therapy , Leprostatic Agents/therapeutic use , Leprosy/drug therapy , Microbial Sensitivity Tests , Mycobacterium Infections, Nontuberculous/drug therapy , Penicillins/therapeutic use , Scabies/drug therapy , Syphilis, Cutaneous/drug therapy , Toxoplasmosis/drug therapy , Tuberculosis, Cutaneous/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL